Regentys Overview

  • Founded
  • 2013
  • Status
  • Acquired/​Merged
  • Employees
  • 4
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $15M
Latest Deal Amount

Regentys General Information


Manufacturer of medical devices created to treat gastrointestinal (GI) disorders. The company manufactures a porcine-derived biological material which acts as a catalyst to stimulate the body to grow new, healthy tissue in place of diseased or damaged tissue and it mainly focuses on tissue-engineered treatment for Inflammatory Bowel Disease (IBD), enabling patients to recover gastrointestinal (GI) disorders.

Contact Information

Ownership Status
(Operating Subsidiary)
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Therapeutic Devices
Parent Company
Primary Office
  • 6135 Northwest 167th Street
  • Suite E15
  • Hialeah, FL 33015
  • United States
+1 (844) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Regentys Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 07-Jan-2019 $15M 00.00 000.00 Completed Generating Revenue
2. Angel (individual) 07-Nov-2016 00.000 00.00 Completed Generating Revenue
1. Accelerator/Incubator 31-Oct-2014 $250K $250K 000 Completed Generating Revenue
To view Regentys’s complete valuation and funding history, request access »

Regentys Executive Team (8)

Name Title Board Seat Contact Info
Richard Bulman Jr. Co-Founder & Chief Executive Officer
Marc Ramer Co-Founder and Consultant
Brian Andersen Chief Business Officer
Steven Wexner Ph.D Chief Medical Officer
Gerard Coombs Co-Founder, Executive Vice President, Operations and Board Member
You’re viewing 5 of 8 executive team members. Get the full list »

Regentys Board Members (8)

Name Representing Role Since
Christine Sapan Ph.D Regentys Co-Founder, Chief Scientific Officer and Board Member 000 0000
Darren Sloniger Self Board Member 000 0000
Hal Wrigley Regentys Board Member 000 0000
Michael Phalen Self Board Member 000 0000
Reginald Hardy Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Regentys Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Regentys Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
43North Accelerator/Incubator Minority 000 0000 000000 0
To view Regentys’s complete investors history, request access »